Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is used in adults. GNH USA supplies Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe is marketed in the European Union and complies with EU pharmaceutical standards.

Olmesartan medoxomil/hydrochlorothiazide is indicated for hypertension management, acting on the renin‑angiotensin‑aldosterone system and fluid balance. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with edema: combines vasodilation with diuresis to control fluid overload. - Hypertension in patients requiring a thiazide diuretic: provides added blood‑pressure reduction when monotherapy is insufficient. - Hypertension in elderly patients: offers effective blood‑pressure control with a once‑daily regimen. - Hypertension with concomitant metabolic syndrome: assists in managing blood pressure alongside metabolic risk factors.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance - Pancreatitis

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; teratogenic risk is possible. - Concomitant drugs: review for interactions with potassium‑sparing agents or NSAIDs. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Aliskiren (in diabetics): increased risk of renal dysfunction. - Lithium: may increase lithium serum concentrations.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hypotension and renal impairment. - Antidiabetic agents: may enhance hypoglycaemic effect. - Antimicroboral agents (e.g., trimethoprim): can affect potassium balance.